Skip to main content

Table 3 Long-term bone crisis and bone pain responses for all symptomatic pediatric GD1 patients at baseline a

From: Long-term effect of imiglucerase in Latin American children with Gaucher disease type 1: lessons from the International Collaborative Gaucher Group Gaucher Registry

Years on imiglucerase

Bone crisis, n (%)

Bone pain, n (%)

 

Yes

No

Yes

No

Baseline, N

N = 24

N = 0

N = 79

N = 0

>0- ≤ 1

0 (0.0)

5 (100.0)

2 (18.2)

9 (81.8)

>1- ≤ 2

0 (0.0)

1 (100.0)

1 (33.3)

2 (66.7)

>2- ≤ 3

0 (0.0)

3 (100.0)

0 (0.0)

5 (100.0)

>3- ≤ 4

0 (0.0)

0 (0.0)

2 (40.0)

3 (60.0)

>4- ≤ 5

0 (0.0)

2 (100.0)

1 (14.3)

6 (85.7)

>5- ≤ 6

0 (0.0)

0 (0.0)

0 (0.0)

10 (100.0)

>6- ≤ 7

1 (33.3)

2 (66.7)

2 (28.6)

5 (71.4)

>7- ≤ 8

0 (0.0)

10 (100.0)

5 (16.1)

26 (83.9)

  1. a‘Baseline’ is defined as the data point closest to the first infusion date, at all time prior to through 2 weeks (inclusive) following first infusion. Patients with no infusion date were excluded from the analysis.
Back to article page

BMC Hematology

ISSN: 2052-1839

Contact us